BRAF inhibitors dabrafenib combined with mitogen‐activated extracellular signal‐regulated kinase (MEK) inhibitors like trametinib could increase anti‐tumor activity and reduce side‐effect.105, 106 In conclusion, targeted therapy such as small molecule kinase inhibitors have achieved outstanding development, but still needs to pay more attention and take more effort on investigation and preferable application in clinic. Here, BRAF is linked to neoplasm.